All Releases
 |
VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
Dec 29, 2009
|
10.6 KB |
|
| |
SAN FRANCISCO, Dec 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications sta...
|
|
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291
Dec 3, 2009
|
10.3 KB |
|
| |
SAN FRANCISCO, Dec 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2...
|
|
VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009
Nov 4, 2009
|
10.5 KB |
|
| |
SAN FRANCISCO, Nov 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "VIA-3196,...
|
|
VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
Oct 29, 2009
|
11.9 KB |
|
| |
SAN FRANCISCO, Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver D...
|
|
VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ
Oct 13, 2009
|
10.2 KB |
|
| |
SAN FRANCISCO, Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market ("...
|
|
VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ
Sep 28, 2009
|
10.4 KB |
|
| |
SAN FRANCISCO, Sept 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on September 23, 2009, it received a deficiency letter from The NASDAQ Stock Market n...
|
|
VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ
Sep 18, 2009
|
10.1 KB |
|
| |
SAN FRANCISCO, Sept 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on September 15, 2009, it received a deficiency letter from the NASDAQ Stock Market s...
|
|
VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
Jul 17, 2009
|
9.8 KB |
|
| |
SAN FRANCISCO, July 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it received a Staff Determination letter, dated July 15, 2009, from the NASDAQ Stock ...
|
|
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Jun 11, 2009
|
10.6 KB |
|
| |
SAN FRANCISCO, June 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that an end of Phase 2a meeting for the Company's lead drug, VIA-2291 (atreleuton), was re...
|
|
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Jun 4, 2009
|
10.5 KB |
|
| |
SAN FRANCISCO, June 4, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that preclinical data related to diacylglycerol acyl transferase - 1 (DGAT1) inhibitors wil...
|
|
VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
May 14, 2009
|
11.8 KB |
|
| |
SAN FRANCISCO, May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed enrollment in a Phase 2 clinical trial of its lead drug, VIA-2291 in ...
|
|
VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
May 1, 2009
|
11.5 KB |
|
| |
WASHINGTON and SAN FRANCISCO, May 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP) today announced the results of a sub-study of patients in its acute coronary syndrome (ACS) Phase 2 trial who received serial 64 slice multidetector computed tomography (MDCT) scans before and after six months of trea...
|
|
VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
Apr 3, 2009
|
9.8 KB |
|
| |
SAN FRANCISCO, April 3, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has received a letter, dated March 31, 2009, from the staff of the NASDAQ Stock Ma...
|
|
VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
Mar 31, 2009
|
10.3 KB |
|
| |
SAN FRANCISCO, March 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that an abstract on the Company's Phase 2 clinical trial of VIA-2291 has been accepted fo...
|
|
VIA Pharmaceuticals Complies With NASDAQ Rules
Mar 27, 2009
|
9.9 KB |
|
| |
SAN FRANCISCO, March 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit rep...
|
|
VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Mar 12, 2009
|
10.3 KB |
|
| |
SAN FRANCISCO, March 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced it has entered into a $10.0 million secured note purchase agreement (together with certai...
|
|
VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
Feb 25, 2009
|
9.6 KB |
|
| |
SAN FRANCISCO, Feb 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for...
|
|
VIA Pharmaceuticals Licenses Drug Candidates from Roche to Expand Cardiovascular Pipeline to Include Metabolic Disease
Dec 23, 2008
|
10.7 KB |
|
| |
SAN FRANCISCO, Dec 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc.
(Nasdaq: VIAP), a biotechnology company focused on the development of
compounds for the treatment of cardiovascular disease, today announced
exclusive, worldwide licensing agreements with Roche (SWX: ROG) for two sets
of compounds. The first ...
|
|
VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
Nov 9, 2008
|
17.2 KB |
|
| |
NEW ORLEANS and SAN FRANCISCO, Nov 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today the results of two Phase 2 studies of its lead drug, VIA-2291. In each Phase 2 study, VIA...
|
|
VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
Nov 6, 2008
|
7.1 KB |
|
| |
SAN FRANCISCO, Nov 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will hold a conference call and webcast to discuss results of the VIA-2291 Phase 2 acute coronary...
|
|
|
